NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

NGM282, an engineered fibroblast growth factor 19 analogue, rapidly and significantly reduced liver fat content in a multicenter, randomized, double‐blind, placebo‐controlled study in patients with biopsy‐confirmed nonalcoholic steatohepatitis (NASH). However, it is unclear whether these changes wou...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatology
Main Authors: Harrison, Stephen A., Rossi, Stephen J., Paredes, Angelo H., Trotter, James F., Bashir, Mustafa R., Guy, Cynthia D., Banerjee, Rajarshi, Jaros, Mark J., Owers, Sandra, Baxter, Bryan A., Ling, Lei, DePaoli, Alex M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187438/
https://ncbi.nlm.nih.gov/pubmed/30805949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30590
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados